Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, our ability to identify and negotiate product partnerships, our ability to raise additional capital to fund our continued operations, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    Lindsey Jesch
    T : 206.272.4347
    F : 206.272.4434
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Fluxion Biosciences announced today that Genetracer Biotech ... appointed as a Certified Service Provider for Fluxion,s IsoFlux ... used in Genetracer Biotech,s novel liquid biopsy workflows for ... with plans to move to other cancers as additional ... System to isolate, recover, and analyze CTCs (circulating tumor ...
(Date:2/25/2017)... New York (PRWEB) , ... February 25, 2017 ... ... partnership with Verified Clinical Trials in an ongoing effort to create ... of treatment, advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... HONG KONG, Feb. 24, 2017 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its unaudited financial results for the ... 2017 ended December 31, 2016. Third Quarter ... the third quarter of fiscal 2017 increased by 18.6% ...
Breaking Biology Technology:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):